Jubilant Pharmova Ltd
Jubilant Pharmova Ltd Q2 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Jubilant Pharmova Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2’FY26 revenue grew by 12% YoY to Rs. Q2’FY26 Financials: - Revenue: Rs.
From Jubilant Pharmova Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2’FY26 revenue grew by 12% YoY to Rs. 1,966 Cr., driven by Radiopharma, Allergy Immunotherapy, CRDMO, and CDMO Sterile Injectables.
- H1’FY26 revenue grew by 11% YoY to Rs. 3,867 Cr. across all business units.
- Radiopharmaceuticals Q2’FY26 revenue rose 16% YoY to Rs. 291 Cr.
- Radiopharmacy Q2’FY26 revenue increased 7% YoY to Rs. 607 Cr.
- Allergy Immunotherapy Q2’FY26 revenue increased 14% YoY to Rs. 194 Cr.
- CDMO Sterile Injectables Q2’FY26 revenue rose 30% YoY to Rs. 393 Cr.
- Generics Q2’FY26 revenue fell 3% YoY to Rs. 167 Cr.
- API Q2’FY26 revenue up 8% YoY to Rs. 137 Cr.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane, USA:
- Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.
- Technology transfer programs ongoing; commercial production expected FY27.
- Line 4 expansion on track; commercial production expected FY28.
- Combined revenue potential for Lines 3 & 4: USD 160-180 million.
- Montreal Facility, Canada:
- Shutdown in Q2’FY26 for quality improvements; restart expected Q3’FY26.
- USD 114 million investment for expansion of sterile fill & lyophilization operations.
- USD 40 million concessional loans from Canadian Government; rest from internal accruals.
- New sterile ophthalmic plant (200-bottle/min) undergoing validation; commercial qualification expected by end FY26.
- Drug Discovery Services:
- Capacity expansion from 1,000 FTEs in FY25 to 4,000 FTEs by FY30.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation does not explicitly quantify the current order book or pending orders.
- For the new third Sterile Fill & Finish line (Line 3) at the Spokane facility, technology transfer programs are ongoing for 5 to 6 products across multiple vial sizes.
- Strong traction witnessed in Requests for Proposals (RFPs) for Line 3, attributed to demand for high-quality US manufacturing amid new tariffs.
- The Company expects to achieve full utilization of Line 3 within the next 3 years.
- Line 4 capacity expansion is on track with commercial production expected by FY28.
2 more points management made on order book & pipeline
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmova Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY25 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q1 FY22 earnings call →
- Q4 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY26 investor presen
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY26 inve
- Lincoln Pharmaceuticals Ltd (Q2 FY26)
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation — and how i
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q2 FY26 results?
Q2’FY26 revenue grew by 12% YoY to Rs. Q2’FY26 Financials: - Revenue: Rs.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane, USA: - Line 3 Sterile Fill & Finish line launched with a total investment of USD 132 million.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.